Many headlines state that Trump is considering finishing the rescheduling process in the next few weeks. These easy scan headlines give the impression that he can just wave a magic wand to make this happen by penning an executive order or simply telling the DEA and DOJ to finish the process.
It’s not quite that simple, and investors may want to know more about this administration’s available options and political hurdles before going all-in on ‘Big Cannabis’.
Why President Trump Can’t Just Reschedule Cannabis Unilaterally
The rules for scheduling drugs are set by the Controlled Substances Act. By law, rescheduling must run through specific agencies and can’t be accomplished by executive order.
Furthermore, rescheduling requires a rigorous scientific evaluation by FDA/HHS, with very few exceptions, and the current recommendation under discussion deviates from the traditional eight-point analysis. So, President Trump might even be limited in terms of political pressure.
This deviation, along with other objections, spurred Nebraska AG Mike Hilgers to pen an objection letter with 11 GOP states that outlines their legal arguments against the current recommendation. This letter basically promises a lawsuit if rescheduling moves forward. In short, Hilgers’ letter argues that:
- The Notice of Proposed Rulemaking is procedurally invalid because it’s not signed by the DEA Administrator (Bondi could cure this defect).
- Rescheduling breaches U.S. treaty obligations.
- HHS’s two-factor test skips required abuse, dependence, and public health analysis.
- Rescheduling will increase cross-border enforcement costs.
If rescheduling moves forward, Hilgers et al. will almost certainly file suit and ask for an injunction based on what they say are concrete and definable harms, and they may even get it. This lawsuit could block any Final Rule and force a full re-evaluation based on traditional factors, and courts have historically blocked attempts to skip CSA procedure.
Unfortunately, this isn’t a process/hot mess that President Trump can bypass with an executive order or any other unilateral action. Beyond this obvious and necessary point, Trump’s statement was hardly a promise to reschedule cannabis in the first place.
What President Trump Actually Said
Trump simply stated they would come to a decision. He didn’t say whether it would be approved, denied, or moved to Schedule 2, 3, or a different Schedule. Specifically, he said: “We’re looking at it. Some people like it, some people hate it. Some people hate the whole concept of marijuana, because if it does bad for the children, it does bad for people that are older than children. But we’re looking at reclassification, and we’ll make a determination over the next, few weeks, and that determination, hopefully, will be the right one. It’s a very complicated subject, you know, the subject of marijuana.”
This is hardly a glowing endorsement of Schedule 3, and this administration is under a lot of pressure from the anti-cannabis establishment to leave cannabis in Schedule 1, or worse for businesses, move it to Schedule 2, which is absolutely an option.
Home / Manufactured Optimism: Why Trump Can’t ‘Just Wave a Magic Wand’ and Reschedule Cannabis
Manufactured Optimism: Why Trump Can’t ‘Just Wave a Magic Wand’ and Reschedule Cannabis
There is a frustrating misimpression circulating in the cannabis community regarding rescheduling.
Many headlines state that Trump is considering finishing the rescheduling process in the next few weeks. These easy scan headlines give the impression that he can just wave a magic wand to make this happen by penning an executive order or simply telling the DEA and DOJ to finish the process.
It’s not quite that simple, and investors may want to know more about this administration’s available options and political hurdles before going all-in on ‘Big Cannabis’.
Why President Trump Can’t Just Reschedule Cannabis Unilaterally
The rules for scheduling drugs are set by the Controlled Substances Act. By law, rescheduling must run through specific agencies and can’t be accomplished by executive order.
Furthermore, rescheduling requires a rigorous scientific evaluation by FDA/HHS, with very few exceptions, and the current recommendation under discussion deviates from the traditional eight-point analysis. So, President Trump might even be limited in terms of political pressure.
This deviation, along with other objections, spurred Nebraska AG Mike Hilgers to pen an objection letter with 11 GOP states that outlines their legal arguments against the current recommendation. This letter basically promises a lawsuit if rescheduling moves forward. In short, Hilgers’ letter argues that:
If rescheduling moves forward, Hilgers et al. will almost certainly file suit and ask for an injunction based on what they say are concrete and definable harms, and they may even get it. This lawsuit could block any Final Rule and force a full re-evaluation based on traditional factors, and courts have historically blocked attempts to skip CSA procedure.
Unfortunately, this isn’t a process/hot mess that President Trump can bypass with an executive order or any other unilateral action. Beyond this obvious and necessary point, Trump’s statement was hardly a promise to reschedule cannabis in the first place.
What President Trump Actually Said
Trump simply stated they would come to a decision. He didn’t say whether it would be approved, denied, or moved to Schedule 2, 3, or a different Schedule. Specifically, he said: “We’re looking at it. Some people like it, some people hate it. Some people hate the whole concept of marijuana, because if it does bad for the children, it does bad for people that are older than children. But we’re looking at reclassification, and we’ll make a determination over the next, few weeks, and that determination, hopefully, will be the right one. It’s a very complicated subject, you know, the subject of marijuana.”
This is hardly a glowing endorsement of Schedule 3, and this administration is under a lot of pressure from the anti-cannabis establishment to leave cannabis in Schedule 1, or worse for businesses, move it to Schedule 2, which is absolutely an option.
US Rescheduling Hearing Nears End as Opposition’s Own Witness Acknowledges Cannabis Fits Schedule III Standard
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
DEA Selects Only Cannabis Opponents For Crucial June 29 Rescheduling Hearing
The Current Political Climate
For now, the most important questions on the table are 'what can President Trump actually do?,' and 'what is he willing to do?'
Here’s what Trump actually has the power to do if he decides he wants cannabis reform to happen pre-midterm election:
This is why we still haven’t seen any movement on rescheduling more than half a year into the new administration.
Yet headlines are literally implying that President Trump could just wave a pen and make it happen. Such blatantly misplaced optimism is almost certainly aimed at warming investor enthusiasm, and it’s misleading at best.
Yes, change is coming at the federal level eventually, but whether this change will benefit existing businesses is highly speculative.
The Political Reality Check
All the ‘Trump can wave a wand’ optimism overlooks this:
In light of the current gunboat diplomacy with South America, we have to realistically consider the political implications of rescheduling beyond the obvious point that the DOJ doesn’t want to give up an enforcement tool right now. Here are just a few of the rescheduling implications under consideration:
The point here is that the decision isn’t taking place in a vacuum, and despite overwhelming public support for cannabis reform, there are powerful forces working against rescheduling. It may take some serious political judo to get past these hurdles.
Rescheduling Judo
Perhaps the real question we should be asking is how this administration could thread the needle and give the appearance of reform while still satisfying hardliners. There’s no question about the political pressure from both sides.
The administration’s Heritage Foundation handlers have the funding and political pull to push for continued criminalization, but midterms are coming and cannabis legalization is an incredibly salient issue with massive public support.
So, might Trump try to pull off some form of rescheduling judo, giving the appearance of progress while still giving in to the hardliners? Absolutely, and Schedule 2 might seem like the perfect solution to an administration trapped between these interests.
Even if Trump “finishes” rescheduling to Schedule 3, expect strings attached. The administration has no interest in giving up cartel enforcement tools in the middle of a Venezuela standoff and a South America drug war narrative. Investors shouldn’t confuse a Schedule III headline with a free-market green rush.
The Drug Policy Alliance recognizes this current political climate, and is collecting signatures to push for complete descheduling. Whether or not this is a realistic ask in the current political environment, it’s worth letting them know our thoughts.
Shaping Cannabis Policy in North America
The regulatory landscape is shifting fast — from state-level reforms to federal oversight and compliance challenges. At Business of Cannabis: New York on Nov 6, 2025, leading policymakers, regulators, legal experts, and operators will share clarity on what’s next for cannabis in North America.
📌 Why attend?
Gain insights into upcoming legislation and compliance frameworks
Hear directly from policy leaders and industry voices shaping the future
Connect with investors, retailers, and operators who need to understand regulation to succeed
Secure your place at the table where the future of cannabis policy will be defined.
Deb Tharp
Other featured articles
Isreal Reopens Canadian Cannabis Dumping Case, This Time With a Route Around Its Finance Minister
By
New Report: Germany’s Cannabis Market Crosses €1.15bn as Reimbursement Era Ends
By
Argent Biopharma’s CannEpil to Target $3bn Veterinary Pain Market, Weeks After Debt-Relief Deal
By
The science of THCV
By
Thailand Presses Medical-Only Cannabis Bill Toward Cabinet as Enforcement Drive Widens
By
Other featured Industry Trends articles
Cannabis Inherits Its Future: Part 1, The Genetic Legacy Loop
By
UK Medical Cannabis Market Growing ‘Faster Than Anyone Expected’
By
Cannabis Europa London 2026: Key Insights, Day 2
By
Cannabis Europa London 2026 – Key Insights, Day 1
By
Jersey’s Cannabis Industry Posts First Profit as Exports Triple, But the Real Value Is Still Leaving the Island
By
Share Article
The Briefing / Newsletter
Insights
you don't want
to miss.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Related news
Isreal Reopens Canadian Cannabis Dumping Case, This Time With a Route Around Its Finance Minister
By
New Report: Germany’s Cannabis Market Crosses €1.15bn as Reimbursement Era Ends
By
Argent Biopharma’s CannEpil to Target $3bn Veterinary Pain Market, Weeks After Debt-Relief Deal
By
The science of THCV
By
Thailand Presses Medical-Only Cannabis Bill Toward Cabinet as Enforcement Drive Widens
By
US Hemp Industry Wins a Stay of Execution as Senate Delays Ban Until December
By
Cannabis Opportunity ‘Greater Today’ Than in 2019, Says the Lender Who Has Committed $550m
By
Spain’s Tobacco Crackdown Could Quietly Wipe Out Its Cannabis Clubs
By
‘Everything in Our Power’: German Patient Groups Fight to Overturn Cannabis Insurance Cuts
By